153052-68-7

Usage

Uses

Used in Organic Synthesis:
Boc-Leu-OH is used as a building block in organic synthesis, particularly for the creation of complex molecules and compounds. Its role in this application is to provide a stable and protected form of the amino acid leucine, which can be further modified or incorporated into larger structures.
Used in Peptide Chemistry:
In peptide chemistry, Boc-Leu-OH is employed as a reagent for the synthesis of peptides. The Boc protecting group allows for the stepwise construction of peptide chains, protecting the amino acid's side chain from unwanted reactions until the desired peptide sequence is achieved.
Used in Pharmaceutical Production:
Boc-Leu-OH is utilized in the production of pharmaceuticals, where it contributes to the synthesis of drug molecules. Its presence in the synthesis process can help in the development of new medications and the improvement of existing ones.
Used in Biochemical Research:
L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-,
(1R)-1-methyl-2-oxo-2-(phenylmethoxy)ethyl ester is also used in biochemical research, where it aids in the study and development of new drugs and biologically active compounds. Boc-Leu-OH can be a valuable tool in understanding the structure and function of peptides and proteins, as well as their interactions with other molecules.
Used in Drug Development:
In the field of drug development, Boc-Leu-OH is employed as a reagent for the synthesis of potential drug candidates. Its use in this context can facilitate the discovery of new therapeutic agents and contribute to advancements in medical treatment.
Used in Environmental and Health Safety Studies:
Due to its potential health hazards and environmental impact, Boc-Leu-OH is also used in studies focused on environmental and health safety. These studies aim to understand the compound's effects on human health and the environment, as well as to develop strategies for safe handling and disposal.

Upstream product

• 53363-89-6 N-t-butoxycarbonyl-N-methyl-L-leucine 
• 2051-96-9 benzyl (R)-Lactate 
• 100-39-0 benzyl bromide 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 2051-96-9 benzyl lactate 
• 56777-24-3 benzyl (S)-Lactate 

Downstream Products

• 133413-70-4 PF1022A antipode 
• 153052-73-4 benzyl N-methyl-L-leucyl-3-phenyl-D-lactyl-N-methyl-L-leucyl-D-lactate 
• 153052-77-8 N-methyl-L-leucyl-3-phenyl-D-lactyl-N-methyl-L-leucyl-D-lactyl-N-methyl-L-leucyl-3-phenyl-D-lactyl-N-methyl-L-leucyl-D-lactic acid 
• 160518-08-1 benzyl N-methyl-L-leucyl-3-phenyl-D-lactyl-N-methyl-L-leucyl-D-lactyl-N-methyl-L-leucyl-3-phenyl-D-lactyl-N-methyl-L-leucyl-D-lactate 
• 153052-74-5 benzyl N-Boc-N-methyl-L-leucyl-3-phenyl-D-lactyl-N-methyl-L-leucyl-D-lactyl-N-methyl-L-leucyl-3-phenyl-D-lactyl-N-methyl-L-leucyl-D-lactate 
• 133413-70-4 8,20-dibenzyl-5,11,17,23-tetraisobutyl-2,4,10,14,16,22-hexamethyl-1,7,13,19-tetraoxa-4,10,16,22-tetraaza-cyclotetracosan-3,6,9,12,15,18,21,24-octaone 

Relevant academic research and scientific papers

ENDOPARASITIC DEPSIPEPTIDES

The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof (1) wherein each of R1, R2, R3, R4, L1, and L2, are as defined herein. The present invention also contemplates compositions and methods of treatment as an endoparasiticide with a Formula (1) compound.

ENDOPARASITIC DEPSIPEPTIDES

The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof wherein each of R1, R2, R3, R4, L1, and L2 are as defined herein. The present invention also contemplates compositions, methods of treatment, and uses as a medicament to treat an animal for an endoparasitic infection with a Formula (1 ) compound.

METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES

The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.

ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS

The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the naturally occurring cyclic depsipeptide PF1022A. The invention also provides compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.

ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS

The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used for combating parasites in or on animals including mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in animals, including birds and mammals.

ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS

The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.

Segment solid-phase total synthesis of the anthelmintic cyclooctadepsipeptides PF1022A and emodepside

Cyclodepsipeptides of the enniation, PF1022 and verticilide families represent a diverse class of highly interesting natural products with respect to their manifold biological activities. However, until now, no practicable solid-phase syntheses of these compounds have been accomplished, probably due to the problematic combination of N-methyl amino acids and hydroxycarboxylic acids. We report herein an efficient synthesis of the anthelmintic PF1022A and its commercial analogue emodepside on Kaiser and Wang resins. Our protocol provides the basis for the solid-phase synthesis of cyclodepsipeptide libraries with a high probability of anthelmintic, antibacterial or insecticidal activity.